Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Opin Pharmacother. 2008 Aug;9(12):2161-73. doi: 10.1517/14656566.9.12.2161 .

Sibutramine: current status as an anti-obesity drug and its future perspectives.

Author information

1
Massachusetts General Hospital, Schizophrenia program, Harvard Medical School, Freedom Trail Clinic, 25 Staniford Street, Boston, MA 02114, USA.

Abstract

BACKGROUND:

Obesity has become a global epidemic with recent estimates of > 400 million obese adults. Despite this, there are few safe and effective pharmacological interventions for obesity. Sibutramine is a weight loss agent, for use as an adjuvant to a comprehensive program of calorie restriction, exercise and behavioral therapy.

OBJECTIVE:

The goal of this article is to review the available literature of pharmacological interventions for obesity and specifically to examine data with sibutramine for the short term on safety and efficacy for weight loss.

METHODS:

The literature on sibutramine was reviewed after a PubMed and Medline search in March 2008. All randomized clinical trails were reviewed.

RESULTS/CONCLUSIONS:

Sibutramine appears to be safe and effective in producing clinically significant weight loss for up to 1 year. Longer prospective clinical studies with sibutramine are needed to evaluate its safety (effect on blood pressure) and ability to maintain weight loss, improve metabolic profiles and reduce the risk of cardiovascular diseases.

PMID:
18671470
DOI:
10.1517/14656566.9.12.2161
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center